What are Aromatase inhibitor drugs?

Aromatase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Aromatase (CYP19A1)). 5 are currently marketed, with 21 more in clinical development.

What are the marketed Aromatase inhibitor drugs?

Marketed Aromatase inhibitor drugs include Anastrozole Tablets, Adjuvant letrozole (postmenopausal women), Arimidex, Teolit, Aromatase inhibitor.

Aromatase inhibitor

5 marketed 17 in Phase 3 4 in Phase 2

This page covers all Aromatase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Aromatase (CYP19A1), aromatase, Aromatase enzyme.

Targets

Aromatase (CYP19A1) · aromatase · Aromatase enzyme · Aromatase · Androgen receptor

Marketed (5)

Anastrozole Tablets · Tolmar Inc. · Oncology
Anastrozole inhibits the enzyme aromatase, which converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels to treat hormone receptor-positive breast cancer.
Adjuvant letrozole (postmenopausal women) · Pfizer · Oncology
Arimidex · AstraZeneca · Oncology
Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer.
Teolit · Oncology
Aromatase inhibitor · Pfizer · Oncology

Phase 3 pipeline (17)

Anastrozole or Letrozole or Exemestane · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · Oncology
These aromatase inhibitors block the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.
Post radiotherapy commencement of anastrozole · Trans Tasman Radiation Oncology Group · Oncology
Anastrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.
Placebo + Letrozole/Anastrozole · Xuanzhu Biopharmaceutical Co., Ltd. · Oncology
Letrozole and Anastrozole are aromatase inhibitors that block the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body.
aromatase inhibition therapy · University of Nebraska · Oncology
Aromatase inhibition therapy works by blocking the enzyme aromatase, which is involved in the production of estrogen.
Anastrazole (Arimidex) · AstraZeneca · Oncology
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.
Anastrozole (Arimidex) · University of British Columbia · Oncology
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women.
Letrozole or Anastrozole Tablets · Jiangsu HengRui Medicine Co., Ltd. · Oncology
Letrozole and Anastrozole are aromatase inhibitors that block the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.
Non-steroidal aromatase inhibitor therapy · Amgen · Oncology
A non-steroidal aromatase inhibitor blocks the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.
Conventional fixed dose letrozole · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Oncology
Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.
Letrozol step up dose · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Oncology
Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women.
Aromatase Inhibitors (Femara) · Dharmais National Cancer Center Hospital · Oncology
Femara (letrozole) inhibits the aromatase enzyme to block conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.
Letrozole Oral Tablet · Eastern Virginia Medical School · Oncology
Letrozole inhibits aromatase, the enzyme responsible for converting androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels.
arimidex dummy · AstraZeneca · Oncology
Arimidex is an aromatase inhibitor that blocks the enzyme responsible for converting androgens to estrogens.
Pre-radiotherapy commencement of anastrozole · Trans Tasman Radiation Oncology Group · Oncology
Anastrozole inhibits aromatase, reducing estrogen levels in postmenopausal women.
ARIMIDEX (anastrazole) · AstraZeneca · Oncology
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women.
Administration of letrozole · IVI Madrid · Oncology
Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women.
Placebo combined with Letrozole · Genor Biopharma Co., Ltd. · Oncology
Letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women, combined with placebo in this trial design.

Phase 2 pipeline (4)

Anastrozole plus Goserelin · Samsung Medical Center · Oncology
Aromatase inhibitor
Anti-aromatase inhibitor · UNICANCER · Oncology
Inhibits the enzyme aromatase
Letrozole Oral Product · Gynaecologisch Oncologisch Centrum Zuid · Oncology
Aromatase inhibitor
Danazol Once Weekly · Lumara Health, Inc. · Oncology
Androgen receptor antagonist